It does validate Novartis' move with MSB to usher in a new era with a respiratory focus.
I posted about this earlier, but in light of this study, here's a revisit!
Just some ball park figures in terms of the global addressable markets...
1. ARDS - USD900M market
2. Allergic Rhinitis - USD7B by 2024
3. COPD - USD14B by 2025
4. CF - USD14B by 2024
5. Asthma - USD20B
6. Smoking cessation - USD64B by 2026
7. Idiopathic pulmonary fibrosis - USD2.8B by 2025
Just on these 7 indications alone, we're looking at a USD122.7 billion market! If Remestemcel addresses just 20% of the market, thats ~USD24B just on these indications alone. The respiratory indications market is larger than we think. Now we have a top-5 pharma company fully bankrolling the studies to treat potentially other indications.
MSB Trading 2020 - a new dawn, page-11488
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
-0.010(0.69%) |
Mkt cap ! $1.644B | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.50 | $1.43 | $4.048M | 2.778M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 26808 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 16001 | 1 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |